Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

sks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


                             PHARMASSET, INC.
            STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
            (in thousands, expect share and per share amounts)



                                              Years Ended September 30,
                                              -------------------------
                                            2009        2008        2007
                                            ----        ----        ----

Revenues                                 $13,293      $1,857     $22,009
                                        --------    --------     -------

COSTS AND EXPENSES:
  Research and development                52,552      42,996      20,319
  General and administrative              13,365      13,289       9,211
                                        --------    --------     -------

           Total costs and expenses       65,917      56,285      29,53
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 BioDelivery Sciences International, Inc. ... Board of Directors has appointed Charles J. (Chuck) ... as members of the Board.  Mr. ... experience in marketing, sales and other commercial functions.  He ... Inc., a development stage company that was recently acquired ...
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ™ ... neuropsychiatric disorders, today announced that enrollment has begun in ... stimulation (eTNS) as adjunctive therapy for the treatment of ... conducted at the Olive View-UCLA Medical Center in ...
(Date:7/21/2014)... ANGELES , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, ... oxide supplements , will celebrate its first anniversary in ... that is designed to enhance the body,s ability to ... formula that is made up of a variety of ... said have been found to increase nitric oxide ...
Breaking Medicine Technology:BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
(Date:7/22/2014)... July 22, 2014 Dimension One Spas’ ... 24 months on all models during the “Let’s Take ... Please visit http://www.d1spas.com/financing for more information and ... Dimension One Spas offers a wide variety of outdoor ... lights, fountains, waterfalls, music, customizable massage, and personal controls. ...
(Date:7/22/2014)... July 22, 2014 Over the ... almost every sphere of human anatomy. In the ... advancements that rendered the possibility of deploying certain ... blood and tissues, in order to detect the ... abnormality. Essentially, In-vitro Diagnostics (IVD) have earned the ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Simple blood tests may one day help predict survival and ... sclerosis (ALS), also called Lou Gehrig,s disease, Italian researchers report. ... clues to how fast ALS is progressing are called albumin ... and liver health, according to the U.S. National Library of ...
(Date:7/22/2014)... of coffee and sit down to read People magazine. How ... you reach for another cup? Would you need more caffeine ... study in the Journal of Consumer Research finds ... and aspirin lose their effectiveness when they engage in more ... it takes for products to wear off. For example, they ...
(Date:7/22/2014)... an astronaut is a much-studied thing. Scientists have analyzed ... even matters of the heart. But for the first ... inflammation caused by the conditions of space flight affect ... fly on the International Space Station. Lessons learned may ... Oxidative stress reflects an imbalance in the body,s ability ...
Breaking Medicine News(10 mins):Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:Why do challenging tasks make consumers believe drugs wear off faster? 2Health News:The heart of an astronaut, five years on 2Health News:The heart of an astronaut, five years on 3
... ... Foundation has teamed up with Pilot Pen to create a line of ... Breast Cancer Foundation is a nonprofit committed to providing direct financial assistance ... early detection and survival of breast cancer. To show support Pilot Pen ...
... ... Products®, a leading direct-to-consumer provider of premium dietary supplements, announces the release of ... ... -- Purity Products®, a leading direct-to-consumer provider of premium dietary supplements, announces the ...
... Research suggests millions are going without needed medical services , ... a history of cancer, particularly people under age 65, are ... the cost of treatment, a new study suggests. , ... quality of life of the 12 million adults in the ...
... ... with the modern and hits big on iTunes store first days of launch , ... New York, NY (PRWEB) June 14, 2010 -- 2010 ... “The Karate Kid”, two events bringing renewed popular interest in Chinese martial arts. , , , ...
... ... of the dangers of cycling injuries and urges caution on the roads , ... (PRWEB) June 14, 2010 -- National Accident Helpline is urging ... weather is seeing an increasing number of people take to their bikes, often for the first ...
... ... production assets, inventory and certain information of the Cell-Pore product group previously owned and ... ... today that it has completed its purchase of the principal manufacturing and production assets, ...
Cached Medicine News:Health News:The American Breast Cancer Foundation Partners with Pilot Pen to Raise Breast Cancer Awareness Nation-Wide 2Health News:The American Breast Cancer Foundation Partners with Pilot Pen to Raise Breast Cancer Awareness Nation-Wide 3Health News:Purity Products Releases Ultimate Sleep Plus Melatonin 2Health News:Cost-Conscious Cancer Survivors Skip Care 2Health News:Cost-Conscious Cancer Survivors Skip Care 3Health News:New iPhone App “Wing Chun Masters” Brings 400-Year-Old Kung Fu To Life Amidst Renewed Popular Interest In Culture. 2Health News:New iPhone App “Wing Chun Masters” Brings 400-Year-Old Kung Fu To Life Amidst Renewed Popular Interest In Culture. 3Health News:Break The Injury Cycle, Says National Accident Helpline 2Health News:CerMedia Completes Purchase of Cell-Pore Principal Assets from NanoDynamics 2